Nucleic Acids Inhibiting LPA Expression for Therapeutic Applications
Summary
The European Patent Office published patent application EP4219716A2 for Silence Therapeutics GmbH, covering nucleic acids designed to inhibit LPA (lipoprotein(a)) expression in cells. The invention includes therapeutic applications for cardiovascular conditions. This A2 publication makes the patent application publicly available with a search report.
What changed
The EPO published patent application EP4219716A2 for nucleic acid compositions that inhibit LPA expression, filed by Silence Therapeutics GmbH. The application names eight inventors including Dames, Schubert, and Tenbaum, with IPC classifications in C12N 15/113 (nucleic acid technology), A61K 31/713 (therapeutic nucleotides), and A61P 9/00 (cardiovascular preparations). The designated states cover all 44 EPC contracting states including Germany, France, UK, Italy, and Spain.
Patent applicants and biotech/pharmaceutical companies developing RNAi or antisense therapeutics targeting lipoprotein(a) should review this publication to assess potential freedom-to-operate implications or licensing opportunities. This A2 publication indicates the application has entered the European phase with a search report attached. No compliance actions are required as this is an informational patent publication.
Source document (simplified)
NUCLEIC ACIDS FOR INHIBITING EXPRESSION OF LPA IN A CELL
Publication EP4219716A2 Kind: A2 Mar 25, 2026
Applicants
Silence Therapeutics GmbH
Inventors
DAMES, Sibylle, SCHUBERT, Steffen, TENBAUM, Stephan, FRAUENDORF, Christian, BETHGE, Lucas, HAUPTMANN, Judith, WEINGÄRTNER, Adrien, RIDER, David Anthony
IPC Classifications
C12N 15/113 20100101AFI20240222BHEP A61K 31/713 20060101ALI20240222BHEP A61P 9/00 20060101ALI20240222BHEP
Designated States
AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR
Named provisions
Related changes
Source
Classification
Who this affects
Taxonomy
Browse Categories
Get Pharma & Drug Safety alerts
Weekly digest. AI-summarized, no noise.
Free. Unsubscribe anytime.
Get alerts for this source
We'll email you when ChangeBridge: EPO Bulletin - Biotech (C12N) publishes new changes.